India’s two Covid-19 vaccines, Covishield and Covaxin have shown efficacy against the Indian strain and have show milder infection after the inoculation, a senior scientist said on Tuesday.
Institute of Genomics and Integrative Biology (IGIB) Director, Anurag Aggarwal said that the study on efficacy of the available vaccines on the B.1.617 variant of Covid-19, also known as the “Double Mutant”, shows that post-inoculation, the infection seems milder.
Agrawal tweeted, “Initial positive neutralization studies of B.1.617, with both post-Covaxin or Covishield sera, are correlatable with milder disease during post-vaccination breakthrough infections. This is a positive while we get quantitative data for better understanding of infection protection.”